Astria Therapeutics Inc R&D Day: Update On STAR-0215 And Its Clinical Development For The Prevention Of HAE Attacks Transcript
Good afternoon. Welcome to the Astria R&D Day. (Operator Instructions) At this time, I would like to turn the call over to your host, Dr. Jill Milne, Co-Founder and CEO of Astria Therapeutics. Please go ahead, Dr.
Hello, everyone. I'm Jill Milne, CEO of Astria Therapeutics. We are very glad to have you here with us today at our first Astria R&D Day. I will start today's event by providing an introduction to our company and our vision for how we believe that our lead product candidate STAR-0215 can positively impact the lives of people living with hereditary angioedema or HAE.
I would like to note that during today's event, as mentioned here, we will make forward-looking statements related to our business based on current and future expectations. Actual results may differ from those indicated by these statements as a result of a variety of risks and uncertainties, including those discussed in our most recent Form 10-K and our subsequent SEC filings. Such
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |